Literature DB >> 23378640

Selection of a high-affinity WW domain against the extracellular region of VEGF receptor isoform-2 from a combinatorial library using CIS display.

Seema Patel1, Pascale Mathonet, Agnes M Jaulent, Christopher G Ullman.   

Abstract

WW domains are small β-sheet motifs that are involved in intracellular signalling through the recognition of proline-rich or phosphorylated linear peptide sequences. Here, we describe modification of this motif to provide a framework for engineering the side chains exposed on its concave surface. This non-natural scaffold incorporates an additional tryptophan, has a shorter loop 1 and supports modification of 25% of the natural protein to form a novel affinity reagent. We demonstrate the utility of this structure by selecting a high-affinity binder to the extracellular region of human vascular endothelial growth factor receptor isoform 2 (VEGFR-2) from a library of modifications, using a cell-free molecular display platform, CIS display. The isolate has low nanomolar affinity to VEGFR-2 and inhibits binding of human VEGF to its receptor with nanomolar activity. The structure is amenable to cyclisation to improve its proteolytic stability and has advantages over larger protein scaffolds in that it can be synthesised chemically to high yields offering potential for therapeutic and non-therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23378640     DOI: 10.1093/protein/gzt003

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  8 in total

1.  Xenoprotein engineering via synthetic libraries.

Authors:  Zachary P Gates; Alexander A Vinogradov; Anthony J Quartararo; Anupam Bandyopadhyay; Zi-Ning Choo; Ethan D Evans; Kathryn H Halloran; Alexander J Mijalis; Surin K Mong; Mark D Simon; Eric A Standley; Evan D Styduhar; Sarah Z Tasker; Faycal Touti; Jessica M Weber; Jessica L Wilson; Timothy F Jamison; Bradley L Pentelute
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-21       Impact factor: 11.205

Review 2.  NextGen protein design.

Authors:  Nicholas Sawyer; Elizabeth B Speltz; Lynne Regan
Journal:  Biochem Soc Trans       Date:  2013-10       Impact factor: 5.407

3.  Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes.

Authors:  Arjun Jain; Shali Chen; Hannah Yong; Subrata Chakrabarti
Journal:  J Diabetes Metab Disord       Date:  2018-10-18

4.  Selection of specific protein binders for pre-defined targets from an optimized library of artificial helicoidal repeat proteins (alphaRep).

Authors:  Asma Guellouz; Marie Valerio-Lepiniec; Agathe Urvoas; Anne Chevrel; Marc Graille; Zaineb Fourati-Kammoun; Michel Desmadril; Herman van Tilbeurgh; Philippe Minard
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

Review 5.  Recent Advances Toward the Discovery of Drug-Like Peptides De novo.

Authors:  Michael Goldflam; Christopher G Ullman
Journal:  Front Chem       Date:  2015-12-18       Impact factor: 5.221

6.  BCPA {N,N'-1,4-Butanediylbis[3-(2-chlorophenyl)acrylamide]} Inhibits Osteoclast Differentiation through Increased Retention of Peptidyl-Prolyl cis-trans Isomerase Never in Mitosis A-Interacting 1.

Authors:  Eugene Cho; Jin-Kyung Lee; Jee-Young Lee; Zhihao Chen; Sun-Hee Ahn; Nam Doo Kim; Min-Suk Kook; Sang Hyun Min; Byung-Ju Park; Tae-Hoon Lee
Journal:  Int J Mol Sci       Date:  2018-11-01       Impact factor: 5.923

7.  Anti-LRP5/6 VHHs promote differentiation of Wnt-hypersensitive intestinal stem cells.

Authors:  Nicola Fenderico; Revina C van Scherpenzeel; Michael Goldflam; Davide Proverbio; Ingrid Jordens; Tomica Kralj; Sarah Stryeck; Tarek Z Bass; Guy Hermans; Christopher Ullman; Teodor Aastrup; Piet Gros; Madelon M Maurice
Journal:  Nat Commun       Date:  2019-01-21       Impact factor: 14.919

Review 8.  Evolving a Peptide: Library Platforms and Diversification Strategies.

Authors:  Krištof Bozovičar; Tomaž Bratkovič
Journal:  Int J Mol Sci       Date:  2019-12-27       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.